Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.

被引：0
|
作者：
Chaft, Jamie E.
Costa, Daniel Botelho
Muzikansky, Alona
Shrager, Joseph B.
Lanuti, Michael
Huang, James
Ramchandran, Kavitha
Rangachari, Deepa
Huberman, Mark
Piotrowska, Zofia
Kris, Mark G.
Azzoli, Christopher G.
Sequist, Lecia V.
Neal, Joel W.
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Stanford Canc Inst, Stanford, CA USA
[6] Massachusetts Gen Hosp, Div Thorac Surg, Boston, MA 02114 USA
[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[8] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[9] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[10] Harvard Med Sch, Boston, MA 02115 USA
[11] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[12] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[13] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
[14] Stanford Univ, Stanford, CA 94305 USA
[15] Stanford Canc Inst, Stanford, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8507
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer
    Neal, Joel W.
    Costa, Daniel B.
    Muzikansky, Alona
    Shrager, Joseph B.
    Lanuti, Michael
    Huang, James
    Ramachandran, Kavitha J.
    Rangachari, Deepa
    Huberman, Mark S.
    Piotrowska, Zofia
    Kris, Mark G.
    Azzoli, Christopher G.
    Sequist, Lecia, V
    Chaft, Jamie E.
    JCO PRECISION ONCOLOGY, 2021, 5 : 325 - 332
  • [2] The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation plus /- Surgery for Stage III EGFR-Mutant NSCLC
    Piper-Vallillo, A.
    Mak, R.
    Lanuti, M.
    Muzikansky, A.
    Rotow, J.
    Janne, P.
    Mino-Kenudson, M.
    Swanson, S.
    Wright, C.
    Kozono, D.
    Marcoux, J.
    Piotrowska, Z.
    Willers, H.
    Sequist, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S188 - S188
  • [3] Clinical outcomes of resected EGFR positive stage I-III NSCLC patients in the Midlands, UK
    Powell, R. L.
    Murukesh, N.
    Seeva, P.
    Solanki, A.
    Singh, A.
    Jain, A.
    Elmasry, A. R.
    Jegannathen, A.
    Irwin, A.
    Ghafoor, Q.
    O'Sullivan, B.
    Taniere, P.
    Baijal, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S731 - S732
  • [4] The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.
    Sequist, Lecia V.
    Willers, Henning
    Lanuti, Michael
    Muzikansky, Alona
    Chen, Aileen B.
    Janne, Pasi A.
    Choi, Noah C.
    Mino-Kenudson, Mari
    Swanson, Scott
    Wright, Cameron D.
    Marcoux, J. Paul
    Piotrowska, Zofia
    Oxnard, Geoffrey R.
    Mak, Raymond H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR
    Dao, T. V.
    Soo, R. A.
    Batra, U.
    Tamayo, M. B. E.
    Tejado Gallegos, L. F.
    Donner, N.
    Alsayed, M.
    Huggenberger, R.
    Reungwetwattana, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S271 - S271
  • [6] Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
    Wu, L.
    Jia, H. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1649 - S1649
  • [7] SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
    Pennell, Nathan A.
    Neal, Joel W.
    Chaft, Jamie E.
    Azzoli, Christopher G.
    Janne, Pasi A.
    Govindan, Ramaswamy
    Evans, Tracey L.
    Costa, Daniel Botelho
    Rosovsky, Rachel Pam Greenerger
    Wakelee, Heather A.
    Heist, Rebecca Suk
    Shaw, Alice Tsang
    Temel, Jennifer S.
    Shapiro, Marc A.
    Muzikansky, Alona
    Lanuti, Michael
    Lynch, Thomas James
    Kris, Mark G.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Prevalence of EGFR mutations in patients with resected stage I-III non-squamous NSCLC: Results from the EARLY-EGFR study.
    Soo, Ross A.
    Reungwetwattana, Thanyanan
    Perroud, Herman Andres
    Batra, Ullas
    Kilickap, Saadettin
    Gallegos, Luis Fernando Tejado
    Donner, Natalia
    Alsayed, Mohamed
    Huggenberger, Reto
    Dao, Tu Van
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Prevalence of EGFR mutations (EGFRm) in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR LATAM
    Amorin, E.
    Perroud, H. A.
    Hellal, L. G-H.
    Francisco, S. V.
    Guerrero, A. P.
    Vasquez, A.
    Gallegos, L. F. T.
    Donner, N.
    Huggenberger, R.
    Corrales, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S739 - S739
  • [10] ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts)
    Rosell, R
    de Lena, M
    Carpagnano, F
    Ramlau, R
    Gonzalez-Larriba, J
    Grodzki, T
    Le Groumellec, A
    Aubert, D
    Gasmi, J
    Douillard, J
    LUNG CANCER, 2005, 49 : S3 - S4
12345